Skye Bioscience reports positive CBeyond Phase 2a extension results for Nimacimab.
ByAinvest
Monday, Feb 2, 2026 7:07 am ET1min read
SKYE--
Skye Bioscience reported positive interim results for its CBeyond Phase 2a extension study on nimacimab in combination with semaglutide. The combination showed a 22.3% total weight loss at 52 weeks, with no plateau observed and potential for further efficacy beyond one year and at higher nimacimab doses. Weight regain during treatment interruption was reduced by over 50%, and the strong safety and tolerability profile was maintained.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet